ATE270327T1 - Verfahren zur präparation von humanem aktiviertem protein c - Google Patents

Verfahren zur präparation von humanem aktiviertem protein c

Info

Publication number: ATE270327T1
Authority: AT; Austria
Prior art keywords: activated protein; protein; human activated; thrombin; activation
Prior art date: 1993-10-29

Application number

AT94931171T

Other languages

English (en)

Inventor

Yoichi Ogata

Toshinobu Nouchi

Shinji Nakahira

Original Assignee

Chemo Sero Therapeut Res Inst

Teijin Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-29

Filing date

1994-10-27

Publication date

2004-07-15

1994-10-27 Application filed by Chemo Sero Therapeut Res Inst, Teijin Ltd filed Critical Chemo Sero Therapeut Res Inst

2004-07-15 Application granted granted Critical

2004-07-15 Publication of ATE270327T1 publication Critical patent/ATE270327T1/de

Links

238000000034 method Methods 0.000 title abstract 2
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
101800004937 Protein C Proteins 0.000 abstract 9
102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 abstract 9
101800001700 Saposin-D Proteins 0.000 abstract 9
229960000856 protein c Drugs 0.000 abstract 9
108090000190 Thrombin Proteins 0.000 abstract 4
229960004072 thrombin Drugs 0.000 abstract 4
108091005804 Peptidases Proteins 0.000 abstract 3
239000004365 Protease Substances 0.000 abstract 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 3
230000004913 activation Effects 0.000 abstract 3
238000002360 preparation method Methods 0.000 abstract 3
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical class CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 abstract 1
150000001768 cations Chemical class 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000746 purification Methods 0.000 abstract 1
238000001179 sorption measurement Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/855—Proteins from animals other than mammals or birds
- Y10S530/856—Snakes; venom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Compounds Of Unknown Constitution (AREA)

AT94931171T 1993-10-29 1994-10-27 Verfahren zur präparation von humanem aktiviertem protein c ATE270327T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP5292499A JP3043558B2 (ja)	1993-10-29	1993-10-29	ヒト活性化プロテインｃ調製物及びその製法
PCT/JP1994/001807 WO1995011966A1 (en)	1993-10-29	1994-10-27	Human activated protein c preparation and process for producing the same

Publications (1)

Publication Number	Publication Date
ATE270327T1 true ATE270327T1 (de)	2004-07-15

Family

ID=17782617

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94931171T ATE270327T1 (de)	1993-10-29	1994-10-27	Verfahren zur präparation von humanem aktiviertem protein c

Country Status (11)

Country	Link
US (1)	US5831025A (de)
EP (1)	EP0726311B1 (de)
JP (1)	JP3043558B2 (de)
KR (1)	KR100383063B1 (de)
CN (1)	CN1123639C (de)
AT (1)	ATE270327T1 (de)
AU (1)	AU680563B2 (de)
CA (1)	CA2175201C (de)
DE (1)	DE69433875T2 (de)
ES (1)	ES2224109T3 (de)
WO (1)	WO1995011966A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2886061B2 (ja) *	1993-10-29	1999-04-26	財団法人化学及血清療法研究所	プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
UA55448C2 (uk)	1997-04-28	2003-04-15	Елі Ліллі Енд Компані	Стійка ліофілізована лікарська форма з активованим білком с (варіанти) та виріб, який її містить
US6630137B1 (en) *	1997-04-28	2003-10-07	Eli Lilly And Company	Activated protein C formulations
US7204981B2 (en)	2000-03-28	2007-04-17	Eli Lilly And Company	Methods of treating diseases with activated protein C
CA2410567A1 (en)	2000-05-24	2001-11-29	Eli Lilly And Company	Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
US20030055003A1 (en) *	2001-07-19	2003-03-20	David Bar-Or	Use of copper chelators to inhibit the inactivation of protein C
AU2003213146A1 (en) *	2002-03-08	2003-09-22	Eli Lilly And Company	Activated protein c formulations
ES2400853T3 (es) *	2002-12-27	2013-04-12	The Chemo-Sero-Therapeutic Research Institute	Agente para mejorar la esperanza de vida en el tratamiento de una neoplasia
AU2013286812B2 (en)	2012-07-04	2017-04-20	Zz Biotech Llc	Treatment of inflammatory skin disorders
PT3137102T (pt)	2014-04-16	2021-09-28	Zz Biotech Llc	Apc para utilização no tratamento de cicatrização cutânea anormal
PL3131572T3 (pl)	2014-04-16	2022-02-07	Zz Biotech Llc	Analog apc do zastosowania w zaleczaniu rany

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4968626A (en) *	1985-08-15	1990-11-06	Board Of Reagents Of The University Of Washington	DNA sequence coding for protein C
WO1989012685A1 (en) *	1987-05-18	1989-12-28	Integrated Genetics, Inc.	Improved protein c molecules and method for making and activating same
US5084274A (en) *	1987-11-17	1992-01-28	Scripps Clinic And Research Foundation	Inhibition of arterial thrombotic occlusion or thromboembolism
WO1991000912A1 (en) *	1989-07-07	1991-01-24	Massachusetts Institute Of Technology	Production and use of hybrid protease inhibitors
WO1991012320A1 (en) *	1990-02-09	1991-08-22	Zymogenetics, Inc.	Activated protein c with truncated light chain
AT402262B (de) *	1991-06-20	1997-03-25	Immuno Ag	Arzneimittel enthaltend aktiviertes protein c
JPH0564588A (ja) *	1991-08-14	1993-03-19	Teijin Ltd	短い重鎖を有するヒトプロテインｃおよび活性化ヒトプロテインｃ

1993
- 1993-10-29 JP JP5292499A patent/JP3043558B2/ja not_active Expired - Lifetime
1994
- 1994-10-27 EP EP94931171A patent/EP0726311B1/de not_active Expired - Lifetime
- 1994-10-27 ES ES94931171T patent/ES2224109T3/es not_active Expired - Lifetime
- 1994-10-27 US US08/637,662 patent/US5831025A/en not_active Expired - Lifetime
- 1994-10-27 KR KR1019960702106A patent/KR100383063B1/ko not_active Expired - Lifetime
- 1994-10-27 AU AU80032/94A patent/AU680563B2/en not_active Expired
- 1994-10-27 AT AT94931171T patent/ATE270327T1/de active
- 1994-10-27 WO PCT/JP1994/001807 patent/WO1995011966A1/ja not_active Ceased
- 1994-10-27 CN CN94194596A patent/CN1123639C/zh not_active Expired - Lifetime
- 1994-10-27 CA CA002175201A patent/CA2175201C/en not_active Expired - Lifetime
- 1994-10-27 DE DE69433875T patent/DE69433875T2/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2175201C (en)	2007-06-12
WO1995011966A1 (en)	1995-05-04
AU680563B2 (en)	1997-07-31
KR100383063B1 (ko)	2003-07-07
CN1138349A (zh)	1996-12-18
EP0726311B1 (de)	2004-06-30
CA2175201A1 (en)	1995-05-04
KR960705921A (ko)	1996-11-08
EP0726311A1 (de)	1996-08-14
ES2224109T3 (es)	2005-03-01
JPH07115972A (ja)	1995-05-09
DE69433875D1 (de)	2004-08-05
DE69433875T2 (de)	2005-07-14
EP0726311A4 (de)	1997-06-11
AU8003294A (en)	1995-05-22
JP3043558B2 (ja)	2000-05-22
US5831025A (en)	1998-11-03
CN1123639C (zh)	2003-10-08

Legal Events

Date

Code

Title

Description

2005-04-15

UEP

Publication of translation of european patent specification

Ref document number: 0726311

Country of ref document: EP

Publication	Publication Date	Title
DE59409712D1 (de)	2001-05-10	Verfahren zur chromatographischen reinigung und trennung von nucleinsäuregemischen
ATE270327T1 (de)	2004-07-15	Verfahren zur präparation von humanem aktiviertem protein c
JPS6485096A (en)	1989-03-30	Hybrid human protein c and biotechnological synthesis thereof
DK0495918T3 (da)	1996-02-19	Aminosyre-beta-lyaseenzyminhibitorer som deodoranter
ID1001B (id)	1996-10-10	Proses dan alat untuk fermentasi asam amino
FI905584A7 (fi)	1991-05-17	Menetelmä 1-(aminometyyli)sykloheksaanietikkahapon valmistamiseksi
DE69011880D1 (de)	1994-10-06	Verfahren zur Herstellung von L-Aminosäuren durch Fermentation.
DE68916754D1 (de)	1994-08-18	Verfahren zur Herstellung von optisch aktiver 3-Hydroxybuttersäure.
ATE264913T1 (de)	2004-05-15	Protease-resistente analoge des thrombomodulin
DE69004229D1 (de)	1993-12-02	Verfahren zur Reinigung von 1,1-Dichlor-1-fluorethan.
DE3683512D1 (de)	1992-03-05	Verfahren zur optischen isomerisierung von optisch aktiver aminosaeure und verfahren zur herstellung von optisch aktiver aminosaeure.
ATE105480T1 (de)	1994-05-15	Thrombin bindende substanz und verfahren zu ihrer herstellung.
AU692988B2 (en)	1998-06-18	Superior thrombomodulin analogs for pharmaceutical use
DE68908576D1 (de)	1993-09-30	Verfahren zur Herstellung von Aktivkohle.
ATE78239T1 (de)	1992-08-15	Verfahren zur herstellung von zeolithen.
ES2096795T3 (es)	1997-03-16	Procedimiento para la separacion de aminoacidos de soluciones acuosas.
ATE4453T1 (de)	1983-09-15	Aminosaeure- und peptidester von leukoindoanilinen, verfahren zu deren herstellung sowie diese verbindungen enthaltende mittel zum nachweis proteolytischer enzyme.
DE59309646D1 (de)	1999-07-22	Verfahren zur Spaltung von Proenzymen
ATE173272T1 (de)	1998-11-15	Verfahren zur reaktivierung von gereinigten membranproteinen
AU2381795A (en)	1996-02-22	Methods for treating bleeding disorders
DE59007810D1 (de)	1995-01-12	Verfahren zur enzymatischen Spaltung von 2-Arylpropionsäurevinylestern.
CA2019872A1 (en)	1991-01-08	Method and kit for determining the functional activity of protein s in human plasma
DE68926922D1 (de)	1996-09-19	Verfahren zur Herstellung von L-alpha-Aminosäuren
DE69614733D1 (de)	2001-10-04	Verfahren zur Herstellung von optisch aktiver Aminosäure
DE3854266D1 (de)	1995-09-07	Verfahren zur Modifizierung eines Molekularsiebes.